Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | PKM | P14618 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476165 | 0.89 | ALDH1A1 (1.00) | KMT2AMEN1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL6237506 | 0.87 | ALDH1A1 (0.81) | KMT2AMEN1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL5251827 | 0.87 | ALDH1A1 (0.81) | KMT2AMEN1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL6948417 | 0.87 | ALDH1A1 (0.81) | KMT2AMEN1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL7510989 | 0.86 | KMT2A (0.82) | KMT2AMEN1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL6792419 | 0.85 | KMT2A (0.88) | KMT2AMEN1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL4714672 | 0.85 | LMNA (0.82) | KMT2AMEN1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL612760 | 0.85 | CYP2C19 (1.00) | KMT2AMEN1ALDH1A1HTTCYP2C19 | |
| SCHEMBL12101129 | 0.85 | PKM (0.75) | KMT2AMEN1ALDH1A1LMNAPKM | |
| SCHEMBL24072635 | 0.84 | RAB9A (0.76) | KMT2AMEN1ALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3456711-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-03-20 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| CN-1745071-A | Novel ethylenediamine derivative | DAIICHI SEIYAKU CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-5618830-A | TREATING INFLUENZA, PREVENTING INFECTION BY INFLUENZA VIRUS | MERCK & CO., INC. (US) | 1997-04-08 | — | — | US | disclosed |
| US-5475109-A | Useful in prevention or treatment of infection by influenza virus | MERCK & CO., INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5070087-A | Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1991-12-03 | — | — | US | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4810713-A | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0235463-A2 | N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-09-09 | — | — | EP | disclosed |
| EP-0228893-A2 | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | KMT2A 3061/4885MEN1 531/4885ALDH1A1 4310/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | KMT2A 2546/4885MEN1 322/4885ALDH1A1 3214/4885 |
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CASP1, CASP14, CASP2 | KMT2A 4574/4885MEN1 3391/4885ALDH1A1 2870/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | KMT2A 3495/4885MEN1 726/4885ALDH1A1 3430/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | KMT2A 3693/4885MEN1 989/4885ALDH1A1 3454/4885 |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CASP1, CASP14, CASP2 | KMT2A 4574/4885MEN1 3391/4885ALDH1A1 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.